A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops ...

Ministry of Health Flags Off Critical Human Immunodeficiency Virus (HIV) Commodities at Mission for Essential Drugs and Supplies (MEDS) ...

An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...

The following is a summary of “Telemedicine virologic and immunologic outcomes in people living with HIV (PLWH) in a ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...